Siekierka-Harreis M, Rump L C, Vonend O
Klinik für Nephrologie, Medizinische Fakultät, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstrasse 5, Düsseldorf, Germany.
Internist (Berl). 2012 Dec;53(12):1411-9. doi: 10.1007/s00108-012-3134-2.
Sympathetic overexpression can be found in a majority of hypertensive patients. Resistant arterial hypertension requires a targeted diagnostic procedure in order to exclude secondary causes of hypertension which can be treated specifically with established therapies. If secondary reasons are not identified, the antihypertensive medication is already optimal and lifestyle changes have been realized, but still the goal of antihypertensive therapy cannot be achieved, alternative invasive therapy strategies such as renal sympathetic denervation and baroreflex activation have been developed to achieve blood pressure control. These therapies are restricted to specialized centers which treat well-defined patients with therapy-resistant hypertension. Little long-term data concerning safety and efficacy are available for the two strategies. However, they should preferably be used as an ultima-ratio and add-on pathway to conservative procedures when established medication fails to achieve blood pressure control. To date, the effectiveness of the interventional antihypertensive therapies has only been shown on patients with systolic blood pressure over 160 mmHg and a mean oral medication of five drugs.
大多数高血压患者存在交感神经过度表达。顽固性动脉高血压需要进行针对性的诊断程序,以排除可通过既定疗法进行特异性治疗的高血压继发原因。如果未发现继发原因,抗高血压药物已达到最佳效果且已实现生活方式改变,但仍无法实现抗高血压治疗目标,则已开发出如肾交感神经去神经支配和压力反射激活等替代性侵入性治疗策略来控制血压。这些疗法仅限于治疗明确的难治性高血压患者的专业中心。关于这两种策略的长期安全性和有效性数据很少。然而,当既定药物未能控制血压时,它们最好用作保守治疗的最终手段和附加途径。迄今为止,介入性抗高血压疗法的有效性仅在收缩压超过160 mmHg且平均口服五种药物的患者中得到证实。